ReproCell Inc
TSE:4978
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ReproCell Inc
Total Liabilities
ReproCell Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ReproCell Inc
TSE:4978
|
Total Liabilities
¥1.6B
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
SanBio Co Ltd
TSE:4592
|
Total Liabilities
¥1.9B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
0%
|
|
|
GNI Group Ltd
TSE:2160
|
Total Liabilities
¥33.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
22%
|
CAGR 10-Years
29%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Liabilities
¥25.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
38%
|
CAGR 10-Years
52%
|
|
|
Takara Bio Inc
TSE:4974
|
Total Liabilities
¥29.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
17%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Total Liabilities
¥555.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
1%
|
|
ReproCell Inc
Glance View
ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
See Also
What is ReproCell Inc's Total Liabilities?
Total Liabilities
1.6B
JPY
Based on the financial report for Dec 31, 2025, ReproCell Inc's Total Liabilities amounts to 1.6B JPY.
What is ReproCell Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
9%
Over the last year, the Total Liabilities growth was -31%. The average annual Total Liabilities growth rates for ReproCell Inc have been 43% over the past three years , 24% over the past five years , and 9% over the past ten years .
